Definitive Contract 75A50119C00022
Award Date 2/1/19
Potential Completion Date 12/31/28
Potential Value $101M
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Cambridge, MA 02142, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $111,268,952.26 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Merck Sharp & Dohme LLC (doing business as Merck), a for-profit pharmaceutical manufacturer. The contract is for the manufacturing and development of the RVSV-ZEBOV vaccine, a critical medical countermeasure. It does not have a set-aside designation. Merck also holds several significant indefinite delivery vehicles...
- This is a $1,754,345,480.45 definitive cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Moderna, Inc. for the development of an mRNA vaccine to licensure for the prevention of COVID-19. The contract includes pre-award costs, development of the mRNA vaccine to Biologics License Application (BLA), and domestic manufacturing scale-out. This award does not have a set-aside designation. Moderna, a for-profit pharmaceutical...
- This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines & Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date...
- <p>This is a cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Janssen Vaccines & Prevention B.V. (JPC), a foreign-owned for-profit organization. The $196,408,488.00 contract does not have a set-aside designation and has an ultimate completion date of March 30, 2026. The contract was awarded on September 28, 2017.</p>
- This is a federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency within the U.S. Department of Health and Human Services, to Profectus Biosciences, Inc., a small business contractor. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a ceiling value of $7,524,330.27 and a period of performance through November 30, 2016. The contract is for the GMP (Good Manufacturing Practice) manufacture of the...
- This is a $149,747,956.00 federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to the Albert B. Sabin Vaccine Institute, Inc. to advance the development of monovalent vaccines for the prevention of Marburg virus (MARV) and Sudan ebolavirus (SUDV) disease. The contract was awarded in September 2019 and has an ultimate completion date of September 30, 2026. This contract was awarded as a Definitive Contract under a Cost No Fee pricing type, with no...
- This is a $762,812,695.00 firm fixed price contract awarded by the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to Emergent Product Development Gaithersburg Inc., a for-profit manufacturer of medical countermeasures. The contract is for the development of medical countermeasures that can be deployed in the event of a filovirus outbreak, which is a crucial component of the U.S. government's outbreak response plan. The...
- This is a $78,296,147.00 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian federal agency, to Merck Sharp & Dohme LLC (Merck) for the development of V920, a vaccine against the Ebola virus using a recombinant vesicular stomatitis virus vector. The contract has an ultimate completion date of September 30, 2024 and does not utilize any set-aside designations. Merck is a prominent pharmaceutical manufacturer...
- This definitive contract was awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Moderna US, Inc. for COVID-19 vaccinations in support of the 2022 Fall Vaccine Campaign. The $7.8 billion firm fixed price contract is a transfer from the original awarding agency, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, and represents continuation of vaccine production...
- This is a $30,559,760.00 cost-plus-fixed-fee delivery order awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Manufacturing Operations Baltimore LLC, a for-profit manufacturer of medical countermeasures. The contract is for the development of the MAPP biopharmaceutical Viral Hemorrhagic Fever (VHF) Medical Countermeasure (MCM) platform. This work is being performed under the Centers for Innovation in...